Document Detail

Isoproterenol-induced myocardial infarction in rabbits. Protection by propranolol or labetalol: a proposed non-invasive procedure.
MedLine Citation:
PMID:  15489129     Owner:  NLM     Status:  MEDLINE    
Myocardial infarction is usually induced in small animals by means of invasive techniques based on mechanical coronary obstruction. As it has been reported that isoproterenol can cause ischemic myocardial alterations, lipid peroxide generation and procoagulant activity, we administered it to rabbits in order to induce a non-invasive myocardial infarction associated with above mentioned cardiovascular risk factors. Considerable ischemic alterations were observed in the animals treated with isoproterenol, including areas of myocardial necrosis, contraction band necrosis, increased plasma levels of cardiac necrosis markers (c-troponin I and myoglobin), and electrocardiographic modifications (ST segment changes and T wave inversion). The myocardial infarction was attributed to the inotropic activity of isoproterenol leading to intracellular calcium overload. The cardiac necrosis phenomena appear to be associated with isoproterenol-induced lipid peroxide generation (as shown by the decrease in plasma Vitamin E levels) and increased procoagulant activity (a shortened PTT). As this model of myocardial damage is based on the use of beta-stimulatory isoproterenol, the beta-blockers propranolol and labetalol were administered to isoproterenol-treated animals. Pretreatment with propranolol or labetalol counteracted the appearance of the myocardial histological alterations and the associated ECG and biochemical lesions. This protective activity was attributed to the beta-blockade. The results of this study demonstrate that myocardial infarction can be induced chemically and non-invasively in small laboratory animals. The procedure is proposed for the study of early ischemic myocardial lesions and the screening of drugs (such as beta-blockers) that can prevent myocardial necrosis damage and the associated risk factors.
Arnaldo Pinelli; Silvio Trivulzio; Livio Tomasoni; Sergio Brenna; Edgardo Bonacina; Roberto Accinni
Related Documents :
2908709 - Left ventricular function and beta-blockers: does intrinsic sympathomimetic activity ha...
679429 - Actions of lidocaine on transmembrane potentials of subendocardial purkinje fibers surv...
3147809 - Nifedipine versus propranolol treatment for unstable angina in the elderly.
835719 - Effects of intravenous anesthetic agents on left ventricular function in dogs.
994539 - Prolonged epicardial mapping in myocardial infarction: the effects of propranolol and i...
3080299 - A seizure induced by concurrent lidocaine-tocainide therapy--is it just a case of addit...
2050829 - Effect of disopyramide on systolic and early diastolic time intervals in patients with ...
21437669 - Age related issues in reperfusion of myocardial infarction.
14721809 - A new clip device for the construction of vascular interrupted anastomoses in congenita...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences     Volume:  23     ISSN:  0928-0987     ISO Abbreviation:  Eur J Pharm Sci     Publication Date:  2004 Nov 
Date Detail:
Created Date:  2004-10-18     Completed Date:  2005-05-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9317982     Medline TA:  Eur J Pharm Sci     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  277-85     Citation Subset:  IM    
Department of Pharmacology, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / therapeutic use*
Labetalol / therapeutic use*
Lipid Peroxides / metabolism
Myocardial Infarction / chemically induced,  prevention & control*
Myocardium / pathology
Partial Thromboplastin Time
Propranolol / therapeutic use*
Vitamin E / blood
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Lipid Peroxides; 1406-18-4/Vitamin E; 36894-69-6/Labetalol; 525-66-6/Propranolol; 7683-59-2/Isoproterenol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Choice of rotation speed (rpm) for bio-relevant drug dissolution testing using a crescent-shaped spi...
Next Document:  Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain tri...